Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel
NASDAQ:ALVO

Alvotech Q3 2026 Earnings Date & Estimates

Alvotech logo
$5.00 -0.31 (-5.84%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$5.00 +0.00 (+0.02%)
As of 10/16/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alvotech is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. The conference call is scheduled for November 12, 2026 at 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Alvotech in Q3 2026

Alvotech is expected to post earnings of -$0.0186 per share on revenue of $139.22 million. In the same quarter a year earlier Alvotech reported -$0.02 per share on revenue of $113.95 million. Alvotech last reported on August 20, 2026, posting -$0.11 per share and missing the -$0.0526 consensus estimate. Alvotech has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.0186
Expected Revenue
$139.22 million
Prior-Year EPS
-$0.02
Prior-Year Revenue
$113.95 million
Expected Revenue Growth
+22.2%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.11 (Missed by -$0.0574)
Last Quarter Revenue
$106.00 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Alvotech Q3 2026 Earnings FAQ

Alvotech (NASDAQ:ALVO) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Alvotech's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Alvotech to post earnings of -$0.0186 per share for Q3 2026.

The consensus revenue estimate for Alvotech is $139.22 million for Q3 2026.

Alvotech Earnings Headlines

Alvotech Stock In Focus After Europe Filing For Eylea 8 Mg Copycat
October 17 at 1:17 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/alvotech-stock-focus-europe-filing-231916905.html
Alvotech, Advanz seek EU nod for high-dose Eylea biosimilar
October 14 at 2:50 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/alvotech-advanz-seek-eu-nod-101639401.html
Buffett's Final Warning: "The Dollar Is Going to Hell"
On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.tc pixel
October 17 at 1:00 AM  |  Decentralized Masters (Ad)
Alvotech and Advanz Pharma File First Known EMA Biosimilar Application for Eylea 8 mg
October 14 at 10:30 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/alvotech-and-advanz-pharma-file-first-known-ema-biosimilar-application-for-eylea-8-mg?utm_source=marketbeat.com&utm_medium=referral
Alvotech And Advanz Pharma Holdco Limited Submit European Regulatory Application For AVT29, Proposed Biosimilar To Eylea 8 Mg
October 14 at 9:49 AM  |  marketscreener.comM
Alvotech and Advanz Pharma Submit AVT29 to EMA as Potential Biosimilar to Eylea HD®
October 14 at 4:51 AM  |  quiverquant.comQ
See More Alvotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alvotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alvotech and other key companies, straight to your email.

About Alvotech

Alvotech (NASDAQ:ALVO) is a biotechnology company focused on developing and manufacturing biosimilar medicines. Biosimilars are biologic products designed to be highly similar to already approved reference medicines and are intended to expand access to treatments while supporting greater affordability.

The company’s pipeline includes biosimilar candidates for conditions in immunology, ophthalmology, oncology and other therapeutic areas. Its development activities cover complex biologic medicines, including treatments used for autoimmune and inflammatory diseases. Alvotech operates an integrated business model spanning cell-line development, process development, clinical testing, regulatory approval and commercial-scale manufacturing.

Founded in Iceland in 2013, Alvotech is headquartered in Reykjavík and serves international markets through a network of commercial and strategic partners. The company’s products and candidates are developed for markets including the United States, Europe and other regions. Alvotech was founded by Robert Wessman, who has also served as the company’s executive chairman.

View Alvotech Profile
Earnings Tools